Humanigen Inc (fka HGENQ)

[VanGan]

Some additional news from Taran Therapeutics regarding lenz. They announced an additional patent, this one for using lenz as a CMML treatment.

https://www.accessnewswire.com/newsroom/en/biotechnology/publication-of-provisional-patent-application-for-lenzilumab-in-chronic-myelomonocyti-1058190

Taran Therapeutics ("Taran") a privately held company focused on hematology/oncology, and with an almost completely enrolled Phase 2/3 trial with lenzilumab, a monoclonal antibody which neutralizes human granulocyte-macrophage colony-stimulating factor ("GM-CSF") showing benefit in this study in treatment-naïve participants with CMML and RAS-pathway mutations, announced the recent publication of a U.S. Non-Provisional Patent Application. The publication number is US-2025-0154243-A1. Under applicable US law, once an application has been published, it is eligible for Provisional Rights. This means that damages may be available for any infringement occurring after the date of publication. The Notice of Publication confirms this patent application has been published by the United States Patent and Trademark Office and covers the treatment of chronic myelomonocytic leukemia with RAS-pathway mutations using Lenzilumab in combination with current standard of care agents.